外周血TSGF、SCC-Ag、CA125水平表达对宫颈癌预后评估的价值

doi:10.3969/j.issn.1671-2587.2019.05.022

临床输血与检验 ›› 2019, Vol. 21 ›› Issue (5): 521-523.DOI: 10.3969/j.issn.1671-2587.2019.05.022

外周血TSGF、SCC-Ag、CA125水平表达对宫颈癌预后评估的价值

席源, 刘永洁, 李祥坤

629000 四川省遂宁市中心医院检验科

收稿日期:2018-01-22 出版日期:2019-10-20 发布日期:2019-10-29
作者简介:席源（1984-）,男,四川遂宁人,主管技师,学士,主要从事肿瘤标志物研究工作,（E-mail）jackyx1017@126.com。

Evaluation of the Level of TSGF,SCC-Ag and CA125 in Peripheral Blood of Patients with Cervical Cancer before Chemotherapy

XI Yuan, LIU Yong-jie, LI Xiang-kun

Department of Clinical Laboratory of Suining Central Aospital,Sichuan 629000

Received:2018-01-22 Online:2019-10-20 Published:2019-10-29

摘要/Abstract

摘要： 目的探究宫颈癌患者化疗前检测外周血中TSGF、SCC-Ag、CA125表达水平对预后的评估价值。方法选取本院2013年1月~2014年1月确诊为I期的宫颈癌患者70例,在治疗结束后随访3年,记录患者肿瘤复发情况,比较不同预后患者化疗前外周血TSGF、SCC-Ag、CA125表达水平,分析上述指标对不同预后的评估价值。结果 3年无复发的患者化疗前外周血TSGF、SCC-Ag、CA125表达水平（54.63±12.35 U/mL、2.42±0.60 μg/L、27.28±12.28 U/mL）明显低于3年内复发患者的（78.29±18.29 U/mL、3.89±1.25 μg/L、36.43±13.05 U/mL）（P<0.05）。Spearman相关性分析显示,患者化疗前外周血TSGF、SCC-Ag、CA125表达水平与治疗后3年内复发风险呈正相关（r=0.535、r=0.329,r=0.744,P<0.05）。进一步的受试者工作特性曲线（ROC）分析结果显示,宫颈癌患者化疗前对外周血TSGF、SCC-Ag、CA125表达水平联合预测其3年内肿瘤复发的敏感度、特异度及准确性均较高。结论早期宫颈癌患者化疗前对外周血TSGF、SCC-Ag、CA125表达水平联合检测的结果可作为患者预后评估的指标之一。

关键词: 肿瘤特异性生长因子, 糖类抗原-125, 磷状细胞癌抗原, 宫颈癌

Abstract: Objective To evaluate the prognostic value of TSGF,SCC-Ag and CA125 in peripheral blood of patients with cervical cancer before chemotherapy.Methods 70 patients with cervical cancer diagnosed with I-II were enrolled in our hospital from January 2013 to January 2014 and were followed up for 3 years after the end of treatment. The recurrence of tumor was recorded and the patients were treated with different prognosis. The expression levels of TSGF,SCC-Ag and CA125 in peripheral blood were detected before and after treatment. The prognostic value of these indexes was analyzed.Results The expression levels of TSGF,SCC-Ag and CA125 in peripheral blood of patients without recurrence（54.63±12.35 U/mL、2.42±0.60 μg/L、27.28±12.28 U/mL） were significantly lower than those in patients with relapse after three years（78.29±18.29 U/mL、3.89±1.25 μg/L、36.43±13.05 U/mL）（P<0.05）.The expression of TSGF,SCC-Ag and CA125 in peripheral blood was positively correlated with the risk of recurrence within three years after treatment （r=0.535,r=0.329,r= 0.744,P<0.05） by Spearman correlation analysis. Further ROC analysis showed that the sensitivity,specificity and accuracy of TSGF,SCC-Ag and CA125 expression in cervical cancer were significantly higher than those in cervical cancer before and after chemotherapy.Conclusion The level of TSGF,SCC-Ag and CA125 in peripheral blood of patients with early cervical cancer before chemotherapy can be used as one of the indicators of prognosis evaluation.

Key words: Tumor-specific growth factor, Carbohydrate antigen-125, Phosphorus cell carcinoma antigen Cervical cancer

中图分类号:

R446.11 R737.33

席源, 刘永洁, 李祥坤. 外周血TSGF、SCC-Ag、CA125水平表达对宫颈癌预后评估的价值[J]. 临床输血与检验, 2019, 21(5): 521-523.

XI Yuan, LIU Yong-jie, LI Xiang-kun. Evaluation of the Level of TSGF,SCC-Ag and CA125 in Peripheral Blood of Patients with Cervical Cancer before Chemotherapy[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(5): 521-523.

参考文献

1 Han J,Guo J. Current evidence and potential mechanisms of therapeutic action of PEDF in cervical cancertreatment[J] .Curr Mol Med,2015,15(5):446-455.
2 李彩文.血清CA125在妇产科疾病诊治中的研究进展[J].现代诊断与治疗,2015,26(9):1951-1952.
3 Dim CC,Onyedum CC,Dim NR,et al. Cervical cancer screening among HIV-positive women in nigeria:An assessment of use and willingness to pay in the absence of donor support[J]. Assoc Provid AIDS Care,2015,14(3):241-244.
4 Gallotta V,Fanfani F,Scambia G. Minilaparoscopic nerve sparing radical hysterectomy in locally advanced cervical cancer after neoadjuvant radiochemotherapy[J].Gynecol Oncol,2014,132(3):758-759.
5 程海荣.年轻早期宫颈癌患者的诊治进展[J].现代肿瘤医学,2016,24(4):678-680.
6 Thulaseedharan JV,Malila N,Hakama M,et al. Socio demographic and reproductive risk factors for cervical cancer-a large prospective cohort study from rural India[J] . Asian Pac J Cancer Prev,2012,13(6):2991-2995.
7 杨文静.恩度联合力扑素同步放疗对中晚期宫颈癌患者血清CYFRA21-1、CEA、SCCA、CA125、IL-8及免疫细胞水平的影响[J].海南医学院学报,2016,22(16):1844-1847.
8 张娟.年轻宫颈癌患者保留生育功能手术治疗的研究进展[J].广西医学,2017,39(5):689-692.
9 吴娣,徐粤,柳洲.血清中CYFRA21-1和SCCAg水平对宫颈癌放疗患者预后分析[J].中国医药导刊,2016,18(11):1087-1088.
10 戴刚毅,杨雪梅,曾守群,等.血清中CYFRA21-1和SCCAg水平对宫颈癌放疗患者预后的评价作用[J].国际检验医学杂志,2017,38(12):1625-1627.
11 董晓霞,黄凌霄,吕杰强,等.血清YKL-40和SCCag联合检测在宫颈癌中的应用价值[J].温州医学院学报,2015,45(3):205-208.
12 李璐,王留兴,许国林,等.血清SccAg、CA125、CA19-9的联合检测对宫颈癌的诊断价值[J].中外医疗,2016,35(14):75-78.
13 刘谢华.COX-2、MMP-9与SCCAg联合检测在宫颈癌早期诊断中的价值[J].中医临床研究,2014,6(20):131-133.
14 周炳辉,张春访.宫颈癌患者血清SCC、CYFRA21-1、CA125、CEA联合检测的临床意义[J].现代中西医结合杂志,2014,23(13):1453-1454.
15 Wang P,Zhu J,Xie XL,et al. Effects on the tumor specific growth factor and tumor necrosis factor α in rats' precancerous lesion of primary hepatocellular carcinoma by direct moxibustion at Ganshu (BL 18) acupoint[J] . Chin J Integr Med,2016,22(7):532-536.
16 冯春翠.宫颈癌患者血清TSGF、SCC含量检测及肿瘤恶性生物学行为的评估[J].海南医学院学报,2015,21(1):105-107.
17 向田.CA125单项与多项肿瘤指标联合检测在卵巢癌诊断中的价值分析[J].河北医药,2017,39(4):520-523.

[1]	严晓春, 李玥, 何飞燕, 胡晓华. miR-205和miR-944在宫颈癌患者血清中的表达及其临床意义[J]. 临床输血与检验, 2021, 23(1): 95-99.
[2]	舒琪, 马辉平, 樊阳阳, 杨雅荣. HMMR-AS1介导EMT在宫颈癌顺铂耐药中的作用^*[J]. 临床输血与检验, 2020, 22(2): 184-190.
[3]	周猷伟, 李绪清, 王彦, 程玲慧, 李洪言. 2018年合肥某院6 912例女性患者人乳头瘤病毒感染状况分析^*[J]. 临床输血与检验, 2019, 21(6): 596-598.
[4]	葛菲, 刘继勇, 黄淑伟, 张龙. SCC、CEA及CYFRA211三者联合检测对早期宫颈癌筛查的临床意义研究^*[J]. 临床输血与检验, 2019, 21(6): 599-603.
[5]	郑辉, 吴赟, 颜辉. 糖蛋白质组学定量方法用于宫颈癌血清标志物筛查的探索[J]. 临床输血与检验, 2016, 18(5): 484-487.
[6]	陈静,李聪. Id-1、VEGF和MMP-9在宫颈鳞状细胞癌中的表达及意义[J]. 临床输血与检验, 2016, 18(2): 137-139.

外周血TSGF、SCC-Ag、CA125水平表达对宫颈癌预后评估的价值

Evaluation of the Level of TSGF,SCC-Ag and CA125 in Peripheral Blood of Patients with Cervical Cancer before Chemotherapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们